Table 1 Baseline laboratory and clinical investigations of the studied groups
Control group | Single infusion | Repeated infusion | P value | |
|---|---|---|---|---|
Age (years) | 49.43 ± 4.53 | 49.63 ± 4.58 | 50.97 ± 4.15 | 1.00 |
Male | 26 (86.7 %) | 25 (83.3 %) | 26 (86.7 %) | 0.923 |
Female | 4 (13.3 %) | 5 (16.7 %) | 4 (13.3 %) | 0983 |
Haemoglobin (g/dl) | 10.33 ± 1.06 | 10.2 ± 1.48 | 10.3 ± 0.77 | 0.614 |
TLC (1000/cm) | 6.07 ± 1.64 | 5.17 ± 2.05 | 6.07 ± 1.14 | 0.520 |
Platelets (1000/cm) | 104 ± 34 | 104 ± 55 | 104 ± 37 | 0.542 |
Total bilirubin (N: 0.1–1 mg/dl) | 3.19 ± 0.89 | 3.59 ± 0.79 | 3.16 ± 0.99 | 0.326 |
Serum albumin (N: 3.4–5.2 g/dl) | 2.8 ± 0.15 | 2.57 ± 0.15 | 2.83 ± 0.16 | 0.291 |
INR (N: 1) | 1.67 ± 0.16 | 1.76 ± 0.22 | 1.68 ± 0.17 | 0.504 |
ALT folds (N: 0–41 IU) | 33.3 ± 16.75 | 32.9 ± 15.07 | 33.3 ± 18.82 | 0.975 |
AST folds (N: 0–37 IU) | 40.63 ± 25.37 | 41 ± 20.31 | 40 ± 29.79 | 0.401 |
AFP | 5.4 ± 3.21 | 8 ± 3.79 | 5.4 ± 2.63 | 0.816 |
Serum creatinine (0.7–1.2 mg/dl) | 1.05 ± 0.15 | 0.92 ± 0.23 | 1.04 ± 0.30 | 0.841 |
Jaundice | 18 (60 %) | 22 (73.3 %) | 21 (70 %) | 0.26 |
Encephalopathy | 14 (46.7 %) | 12 (40 %) | 13 (43.3 %) | 0.81 |
Lower limb oedema | 20 (67.7 %) | 20 (67.7 %) | 19 (63.3 %) | 0.45 |
Bleeding tendency | 23 (76.7 %) | 24 (80 %) | 22 (73.3 %) | 0.56 |
Haematemesis | 14 (46.7 %) | 13 (43.3 %) | 15 (50 %) | 0.82 |